A Study of TMC435 in Combination With Peginterferon Alfa-2A and Ribavirin for Hepatitis C Virus Genotype-1 Infected Patients Who Participated in a Control Group of a TMC435 Study
7/3/2013

California, Florida, Louisiana, Mississippi, North Carolina, Ohio, Pennsylvania, Texas, Argentina, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russia, Spain, Turkey, Ukraine, United Kingdom. clinicaltrials.gov

Related Summaries